UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

Cancer cell, 2014-08, Vol.26 (2), p.177-189

2014

Volltextzugriff (PDF)

Death receptor agonist therapies for cancer, which is the right TRAIL?

Cytokine & growth factor reviews, 2014-04, Vol.25 (2), p.185-193

Holland, Pamela M

2014

Volltextzugriff (PDF)

Endogenous IL-27 during toxoplasmosis limits early monocyte responses and their inflammatory activation by pathological T cells

mBio, 2024-03, Vol.15 (3), p.e0008324-e0008324

2024

Volltextzugriff (PDF)

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Journal for immunotherapy of cancer, 2020-04, Vol.8 (1), p.e000413

2020

Volltextzugriff (PDF)

Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL

Cancer letters, 2013-05, Vol.332 (2), p.156-162

Holland, Pamela M

2013

Volltextzugriff (PDF)

Therapeutic potential of cis-targeting bispecific antibodies

Cell chemical biology, 2024-08, Vol.31 (8), p.1473-1489

2024

Volltextzugriff (PDF)

Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases

Arthritis & rheumatology (Hoboken, N.J.), 2023-07, Vol.75 (7), p.1187-1202

2023

Volltextzugriff (PDF)

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

Cancer biology & therapy, 2010-04, Vol.9 (7), p.539-550

2010

Volltextzugriff (PDF)

Non‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101)

Arthritis & rheumatology (Hoboken, N.J.), 2023-08, Vol.75 (8), p.1344-1356

2023

Volltextzugriff (PDF)

Multiple Signaling Pathways for the Activation of JNK in Mast Cells: Involvement of Bruton's Tyrosine Kinase, Protein Kinase C, and JNK Kinases, SEK1 and MKK7

The Journal of immunology (1950), 1998-08, Vol.161 (4), p.1795-1802

1998

Volltextzugriff (PDF)

RIP4 Regulates Epidermal Differentiation and Cutaneous Inflammation

Journal of investigative dermatology, 2010-01, Vol.130 (1), p.102-112

2010

Volltextzugriff (PDF)

Purification, Cloning, and Characterization of Nek8, a Novel NIMA-related Kinase, and Its Candidate Substrate Bicd2

The Journal of biological chemistry, 2002-05, Vol.277 (18), p.16229-16240

2002

Volltextzugriff (PDF)

Protein modification: Docking sites for kinases

Current biology, 1999-05, Vol.9 (9), p.R329-R331

1999

Volltextzugriff (PDF)

Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells

Apoptosis (London), 2007-08, Vol.12 (8), p.1465-1478

2007

Volltextzugriff (PDF)

RIP4 Is an Ankyrin Repeat-Containing Kinase Essential for Keratinocyte Differentiation

Current biology, 2002-08, Vol.12 (16), p.1424-1428

2002

Volltextzugriff (PDF)

MKK7 Is A Stress-activated Mitogen-activated Protein Kinase Kinase Functionally Related to hemipterous

The Journal of biological chemistry, 1997-10, Vol.272 (40), p.24994-24998

1997

Volltextzugriff (PDF)

Protein kinase C-associated kinase is not required for the development of peripheral B lymphocyte populations

Molecular Immunology, 2006-04, Vol.43 (10), p.1694-1699

2006

Volltextzugriff (PDF)

Abstract 4548: SRF813, a fully human monoclonal antibody targeting the inhibitory receptor CD112R, enhances immune cell activation and demonstrates preclinical in vivo anti-tumor activity

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4548-4548

2020

Volltextzugriff (PDF)

Abstract 1802: CD39 inhibition shapes the transcriptional landscape of myeloid cells and induces proinflammatory states in the CT26 syngeneic tumor model

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1802-1802

2021

Volltextzugriff (PDF)

Abstract 6639: SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6639-6639

2020

Volltextzugriff (PDF)

Abstract 4550: Increased IL-27 is associated with poor prognosis in renal cell carcinoma and supports use of SRF388, a first-in-class IL-27p28 blocking antibody, to counteract IL-27-mediated immunosuppression in this setting

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4550-4550

2020

Volltextzugriff (PDF)

Abstract 558: MERTK-specific antibodies that have therapeutic antitumor activity in mice disrupt the integrity of the retinal pigmented epithelium in cynomolgus monkeys

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.558-558

2019

Volltextzugriff (PDF)

Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas

Blood, 2018-11, Vol.132 (Supplement 1), p.339-339

2018

Volltextzugriff (PDF)

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

Blood, 2018-11, Vol.132 (Supplement 1), p.4393-4393

2018

Volltextzugriff (PDF)

CD47 Monoclonal Antibody SRF231 Is a Potent Inducer of Macrophage-Mediated Tumor Cell Phagocytosis and Reduces Tumor Burden in Murine Models of Hematologic Malignancies

Blood, 2016-12, Vol.128 (22), p.1843-1843

2016

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(38)
Buchkapitel
(1)

Sprache

Englisch
(39)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

Death receptor agonist therapies for cancer, which is the right TRAIL?

Endogenous IL-27 during toxoplasmosis limits early monocyte responses and their inflammatory activation by pathological T cells

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL

Therapeutic potential of cis-targeting bispecific antibodies

Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

Non‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101)

Multiple Signaling Pathways for the Activation of JNK in Mast Cells: Involvement of Bruton's Tyrosine Kinase, Protein Kinase C, and JNK Kinases, SEK1 and MKK7

RIP4 Regulates Epidermal Differentiation and Cutaneous Inflammation

Purification, Cloning, and Characterization of Nek8, a Novel NIMA-related Kinase, and Its Candidate Substrate Bicd2

Protein modification: Docking sites for kinases

Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells

RIP4 Is an Ankyrin Repeat-Containing Kinase Essential for Keratinocyte Differentiation

MKK7 Is A Stress-activated Mitogen-activated Protein Kinase Kinase Functionally Related to hemipterous

Protein kinase C-associated kinase is not required for the development of peripheral B lymphocyte populations

Abstract 4548: SRF813, a fully human monoclonal antibody targeting the inhibitory receptor CD112R, enhances immune cell activation and demonstrates preclinical in vivo anti-tumor activity

Abstract 1802: CD39 inhibition shapes the transcriptional landscape of myeloid cells and induces proinflammatory states in the CT26 syngeneic tumor model

Abstract 6639: SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies

Abstract 4550: Increased IL-27 is associated with poor prognosis in renal cell carcinoma and supports use of SRF388, a first-in-class IL-27p28 blocking antibody, to counteract IL-27-mediated immunosuppression in this setting

Abstract 558: MERTK-specific antibodies that have therapeutic antitumor activity in mice disrupt the integrity of the retinal pigmented epithelium in cynomolgus monkeys

Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

CD47 Monoclonal Antibody SRF231 Is a Potent Inducer of Macrophage-Mediated Tumor Cell Phagocytosis and Reduces Tumor Burden in Murine Models of Hematologic Malignancies

Suchergebnisse filtern